Rafferty Domnick Cunningham & Yaffa On What the FDA’s Latest Warning to Olympus Means for Medical Device Accountability
Katherine A. Kiziah, a partner at Rafferty Domnick Cunningham & Yaffa (RDCY), was featured in a GlobeNewswire article examining the implications of the U.S. Food and Drug Administration’s latest warning letter to Olympus Corporation and its broader significance for medical device safety and manufacturer accountability.
The FDA warning, dated October 7, 2026, addresses concerns involving quality management systems and regulatory compliance processes at six Olympus facilities across Japan, Germany, and the United States. The development follows years of regulatory scrutiny involving the medical device manufacturer, including previous FDA warnings, criminal penalties, and import restrictions affecting certain products.
Kiziah, whose practice focuses on complex product liability, mass tort, pharmaceutical, and medical device litigation, emphasized the importance of examining whether Olympus has implemented effective, lasting corrective measures. She explained that patient safety depends not only on individual device performance but also on manufacturers maintaining reliable systems for investigating complaints, identifying risks, reporting adverse events, and preventing recurring problems.
The coverage also distinguishes the latest regulatory concerns from findings of specific product defects or patient injuries. Olympus maintains that its products remain safe when used as directed and that the warning does not require a recall.
Rafferty Domnick Cunningham & Yaffa continues to monitor medical device safety developments and represent individuals and families in litigation involving allegedly dangerous products and corporate misconduct.
